Recommended primary outcomes for clinical trials evaluating hemostatic blood products and agents in patients with bleeding: Proceedings of a National Heart Lung and Blood Institute and US Department of Defense Consensus Conference
Philip C. Spinella(University of Pittsburgh), Christopher S. Almond(Stanford University), Nigel S. Key(University of North Carolina at Chapel Hill), Simon Stanworth(NHS Blood and Transplant), Alan Barkun(McGill University Health Centre), Ernest E. Moore(Denver Health Medical Center), John B. Holcomb(Uniformed Services University of the Health Sciences), Alfonso Iorio(Impact), Joshua N. Goldstein(Massachusetts General Hospital), Jerrold H. Levy(Duke University), Roger Lewis(University of California, Los Angeles), Nahed El Kassar, Terry Gernsheimer(Bloodworks Northwest), Dennis M. Jensen(University of California, Los Angeles), Andrei Kindzelski(National Institutes of Health), Stephan A. Mayer(Westchester Medical Center), Marie E. Steiner(Boston University)
Cited by 32
Related Papers
Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct
|New England Journal of Medicine|2017|5.5k
Genomic responses in mouse models poorly mimic human inflammatory diseases
|Proceedings of the National Academy of Sciences|2013|3k